Dextroamphetamine is a central nervous system stimulant sold in the U.S. under 3 brand and generic names, for attention deficit disorder with hyperactivity and narcolepsy. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
From the FDA label for Dexedrine Spansule (application NDA017078). Other dextroamphetamine products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
Amphetamines should be administered at the lowest effective dosage and dosage should be individually adjusted. Late evening doses should be avoided because of the resulting insomnia. Narcolepsy Usual dose is 5 to 60 mg per day in divided doses, depending on the individual patient response. Narcolepsy seldom occurs in children under 12 years of age; however, when it does, dextroamphetamine sulfate may be used. The suggested initial dose for patients aged 6 to 12 is 5 mg daily; daily dose may be raised in increments of 5 mg at weekly intervals until an optimal response is obtained. In patients 12 years of age and older, start with 10 mg daily; daily dosage may be raised in increments of 10 mg at weekly intervals until an optimal response is obtained. If bothersome adverse reactions appear (e.g., insomnia or anorexia), dosage should be reduced. Extended-release capsules may be used for once-a-day dosage wherever appropriate. Attention Deficit Disorder with Hyperactivity The extended-release capsule formulation is not recommended for pediatric patients younger than 6 years of age. In pediatric patients 6 years of age and older, start with 5 mg once or twice daily; daily dosage may be raised in increments of 5 mg at weekly intervals until optimal response is obtained. Only in rare cases will it be necessary to exceed a total of 40 mg per day. Extended-release capsules may be used…
Cardiovascular Palpitations, tachycardia, elevation of blood pressure. There have been isolated reports of cardiomyopathy associated with chronic amphetamine use. Central Nervous System Psychotic episodes at recommended doses (rare), overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, tremor, headache, exacerbation of motor and phonic tics, and Tourette’s syndrome. Gastrointestinal Dryness of the mouth, unpleasant taste, diarrhea, constipation, other gastrointestinal disturbances. Anorexia and weight loss may occur as undesirable effects. Allergic Urticaria. Endocrine Impotence, changes in libido, frequent or prolonged erections. Musculoskeletal Rhabdomyolysis. Skin and Subcutaneous Tissue Disorders Alopecia. To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
| # | Drug | Rating | Type | Form | Generic? | Typical price | |
|---|---|---|---|---|---|---|---|
| 1 | 72/100 | Prescription | Capsule | Generic | $30 | View → | |
| 2 |
Imprint codes, colour and shape from the FDA’s labelling data. Match the imprint on your pill — or search any imprint.
| Imprint | Strength | Colour | Shape | Maker |
|---|---|---|---|---|
| Lannett;0791 | 2.5 mg / 2.5 mg / 2.5 mg / 2.5 mg | blue, blue | capsule | — |
| LANNETT;0790 | 1.25 mg / 1.25 mg / 1.25 mg / 1.25 mg | blue, white | capsule | — |
| Lannett;0792 | 3.75 mg / 3.75 mg / 3.75 mg / 3.75 mg | white, blue | capsule | — |
| Lannett;0793 | 5 mg / 5 mg / 5 mg / 5 mg | orange, orange | capsule | — |
| Lannett;0794 | 6.25 mg / 6.25 mg / 6.25 mg / 6.25 mg | white, orange | capsule | — |
A combination is a different drug — different dosing, different warnings. It is listed here so you can find it, not so you can substitute it.
From the FDA Enforcement database. A recall covers specific lots — not the drug as a whole.
Dextroamphetamine Saccharate
Failed Impurities/Degradation Specifications:
Granules Pharmaceuticals Inc. · Aug 28, 2025
Dextroamphetamine Saccharate
Failed Impurities/Degradation Specifications:
Granules Pharmaceuticals Inc. · Aug 28, 2025
Dextroamphetamine Saccharate
Failed Impurities/Degradation Specifications:
Granules Pharmaceuticals Inc. · Aug 28, 2025
Dextroamphetamine Saccharate
Failed Impurities/Degradation Specifications:
Granules Pharmaceuticals Inc. · Aug 28, 2025
Dextroamphetamine Saccharate
Failed Impurities/Degradation Specifications:
Granules Pharmaceuticals Inc. · Aug 28, 2025
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines, glaucoma. Agitated states. Patients with a history of drug abuse. Known hypersensitivity or idiosyncrasy to amphetamine. In patients known to be hypersensitive to amphetamine, or other components of dextroamphetamine sulfate. Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ]. Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see Warnings and Drug Interactions ].
Acidifying Agents Lower blood levels and efficacy of amphetamines. Increase dose based on clinical response. Examples of acidifying agents include gastrointestinal acidifying agents (e.g., guanethidine, reserpine, glutamic acid hydrochloride, ascorbic acid) and urinary acidifying agents (e.g., ammonium chloride, sodium acid phosphate, methenamine salts). Adrenergic Blockers Adrenergic blockers are inhibited by amphetamines. Alkalinizing Agents Increase blood levels and potentiate the action of amphetamine. Co-administration of dextroamphetamine sulfate and gastrointestinal alkalinizing agents should be avoided. Examples of alkalinizing agents include gastrointestinal alkalinizing agents (e.g., sodium bicarbonate) and urinary alkalinizing agents (e.g. acetazolamide, some thiazides). Tricyclic Antidepressants May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated. Monitor frequently and adjust or use alternative therapy based on clinical response. Examples of tricyclic antidepressants include desipramine, protriptyline. CYP2D6 Inhibitors The concomitant use of dextroamphetamine sulfate and CYP2D6 inhibitors may increase the exposure of dextroamphetamine sulfate compared to the use of the drug alone and increase the risk…
| 72/100 |
| Prescription |
| Capsule |
| Generic |
| $30 |
| View → |
| 3 | 64/100 | Prescription | Patch | Generic | $30 | View → |
| Lannett;0795 | 7.5 mg / 7.5 mg / 7.5 mg / 7.5 mg | orange, white | capsule | — |
|---|
| AMG;277 | 1.25 mg / 1.25 mg / 1.25 mg / 1.25 mg | white, green | capsule | — |
|---|
| AMG;278 | 2.5 mg / 2.5 mg / 2.5 mg / 2.5 mg | green | capsule | — |
|---|
| G454 | 5 mg / 5 mg / 5 mg / 5 mg | brown, brown | capsule | — |
|---|
| G456 | 7.5 mg / 7.5 mg / 7.5 mg / 7.5 mg | brown, brown | capsule | — |
|---|
| u;31 | 7.5 mg / 7.5 mg / 7.5 mg / 7.5 mg | orange | round | — |
|---|
| G453 | 3.75 mg / 3.75 mg / 3.75 mg / 3.75 mg | turquoise, white | capsule | — |
|---|